

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A method for the *in vitro* culture of a myeloma cell line
wherein the method comprises~~which comprises~~:
 - (a) inoculating a culture medium with a myeloma cell line, said medium being capable of supporting the growth of said myeloma cell line and comprising iron at concentrations in the medium of from about 0.03 mg/L to about 3.2 mg/L, wherein said medium does not contain transferrin, a lipophilic chelator, a synthetic nitrogen-containing chelator or a lipophilic synthetic nitrogen-containing chelator ; and
 - (b) growth of the inoculated culture medium under appropriate conditions and using agitated suspension culture.
2. (Original) The method of claim 1 wherein the concentration of iron in the medium is from about 0.03mg/L to about 2.4 mg/L.
3. (Original) The method of claim 1 wherein the concentration of iron in the medium is from about 0.064 mg/L to about 1.6 mg/L.
4. (Original) The method of claim 1 wherein the concentration of iron in the medium is from about 0.16 mg/L to about 0.32 mg/L.
5. (Original) The method of claim 1 wherein the source of iron is a soluble iron compound.
6. (Original) The method of claim 5 wherein the soluble iron compound is selected from the group consisting of ferrous or ferric salts or simple chelates thereof.

7. (Original) The method of claim 6 wherein the soluble iron compound is selected from the group consisting of ferrous sulphate, ferrous citrate, ferric citrate and ferric ammonium compounds.

8. (Original) The method of claim 7 wherein the ferric ammonium compound is selected from the group consisting of ferric ammonium citrate, ferric ammonium oxalate, ferric ammonium fumarate, ferric ammonium malate and ferric ammonium succinate.

9. (Original) The method of claim 7 wherein the ferric ammonium compound is ferric ammonium citrate.

10. (Currently Amended) A method for the *in vitro* culture of a myeloma cell line wherein the method comprises~~which comprises~~:

- (a) inoculating a culture medium with a myeloma cell line, said medium being capable of supporting the growth of said myeloma cell line and comprising ferric ammonium citrate at a concentration in the medium of from about 0.2 mg/L to about 20 mg/L, wherein said medium does not contain transferrin, a lipophilic chelator, a synthetic nitrogen-containing chelator or a lipophilic synthetic nitrogen-containing chelator ; and
- (b) growth of the inoculated culture medium under appropriate conditions and using agitated suspension culture.

11. (Original) The method of claim 10 wherein the ferric ammonium citrate is present in the medium at a concentration of from about 0.2 mg/L to about 15 mg/L.

12. (Original) The method of claim 10 wherein the ferric ammonium citrate is present in the medium at a concentration of from about 0.4 mg/L to about 10 mg/L.

13. (Original) The method of claim 10 wherein the ferric ammonium citrate is present in the medium at a concentration of from about 1 mg/L to about 2mg/L.

14. (Previously Presented) The method of claim 1 wherein the medium is serum free, protein free, free of components of animal derivation or is chemically defined.

15. (Previously Presented) The method of claim 1 wherein the myeloma cell line is selected from the group consisting of an NSO series, a P3 series, MOPC series, MPC-11, J558L, K6H6/B5, 45.6.TG1.7, Y0, Y3 HTK, RPMI 8226 and U266B1.

16. (Previously Presented) The method of claim 1 wherein the myeloma cell line is an NSO cell line.

Claims 17-32. (Canceled)

33. (Previously Presented) A process for obtaining a mammalian cell product comprising culturing a myeloma cell capable of producing said product under agitated suspension culture and in a culture medium capable of supporting the growth of said myeloma cell line, said medium comprising iron at concentrations in the medium of from about 0.03 mg/L to about 3.2 mg/L, or ferric ammonium citrate at a concentration in the medium of from about 0.2 mg/L to about 20 mg/L, wherein said medium does not contain transferrin, a lipophilic chelator, a synthetic nitrogen-containing chelator or a lipophilic synthetic nitrogen-containing chelator; and recovering said mammalian cell product.

34. (Original) The process of claim 33 wherein the concentration of iron in the medium is from about 0.03 mg/L to about 2.4 mg/L.

35. (Original) The process of claim 33 wherein the concentration of iron in the medium is from about 0.064 mg/L to about 1.6 mg/L.

36. (Original) The process of claim 33 wherein the concentration of iron in the medium is from about 0.16 mg/L to about 0.32 mg/L.

37. (Original) The process of claim 33 wherein the source of iron is a soluble iron compound.

38. (Original) The process of claim 37 wherein the soluble iron compound is selected from the group consisting of ferrous or ferric salts or simple chelate thereof.

39. (Original) The process of claim 37 wherein the soluble iron compound is selected from the group consisting of ferrous sulphate, ferrous citrate, ferric citrate and ferric ammonium compounds.

40. (Original) The process of claim 39 wherein the ferric ammonium compound is selected from the group consisting of ferric ammonium citrate, ferric ammonium oxalate, ferric ammonium fumarate, ferric ammonium malate and ferric ammonium succinate.

41. (Original) The process of claim 40 wherein the ferric ammonium compound is ferric ammonium citrate.

Claim 42. (Canceled)

43. (Previously Presented) The process of claim 33 wherein the ferric ammonium citrate is present in the medium at a concentration of from about 0.2 mg/L to about 15 mg/L.

44. (Previously Presented) The process of claim 33 wherein the ferric ammonium citrate is present in the medium at a concentration of from about 0.4 mg/L to about 10 mg/L.

45. (Previously Presented) The process of claim 33 wherein the ferric ammonium citrate is present in the medium at a concentration of from about 1 mg/L to about 2 mg/L.

46. (Previously Presented) The process of claim 33 wherein the medium is serum free, protein free, free of components of animal derivation or is chemically defined.

47. (Previously Presented) The process of claim 33 wherein the myeloma cell line is selected from the group consisting of an NSO series, a P3 series, MOPC series, MPC-11, J558L, K6H6/B5, 45.6.TG1.7, Y0, Y3 HTK, RPMI 8226 and U266B1.

48. (Previously Presented) The process of claim 33 wherein the myeloma cell line is an NSO cell line.

49. (Previously Presented) The process of claim 33 wherein the cell product is selected from the group consisting of polypeptides, proteins, hormones, lymphokines, interleukins and industrially and therapeutically useful enzymes.

50. (Original) The process of claim 49 wherein the cell product is an antibody or fragment thereof.